Hyaluronic acid-coated branched cell-penetrating peptide nanoparticles delivered methotrexate selectively to CD44-overexpressing cancer cells with glutathione-triggered drug release and superior in vivo tumor inhibition.
CD44-mediatedtargeting of cancer cells through hyaluronic acid coating on cell-penetrating peptide nanoparticles
What the researchers found
B-mR9-MTX/HA nanoparticles demonstrated glutathione-triggered degradability, CD44-mediated cancer cell targeting, efficient intracellular methotrexate delivery, and superior tumor inhibition in vivo.
Why it matters
Targeted drug delivery could improve cancer treatment by getting more drug to tumor cells while reducing side effects. Using cell-penetrating peptides as the delivery backbone adds the ability to enter cells efficiently, while the targeting and triggered-release features add specificity.
The numbers in context
B-mR9/HA nanoparticles achieved selective CD44-mediated uptake and redox-triggered MTX release in cancer cells.
How the study worked
Synthesis of branched modified nona-arginine (B-mR9) with redox-cleavable disulfide bonds. Methotrexate loading and hyaluronic acid coating. In vitro CD44-mediated uptake studies. In vivo tumor inhibition study.
Who was studied
CD44-positive cancer cell lines
What this study cannot tell us
Early-stage in vivo data without detailed pharmacokinetics or toxicity profiles. CD44 is expressed on some normal cells, potentially causing off-target effects. Manufacturing complexity of multi-component nanoparticles may limit clinical translation.
How to read the evidence
Proof-of-concept with both in vitro targeting confirmation and in vivo tumor inhibition. Early-stage but demonstrates multi-functional nanomedicine design.
When this study was published
Published in 2020. Peptide-based nanomedicine for targeted cancer therapy continues to be actively developed.
The bigger picture
Smart nanoparticles that combine targeting, cell penetration, and triggered drug release represent the cutting edge of drug delivery. This peptide-based platform addresses multiple challenges simultaneously — toxicity, specificity, and efficacy — in a single nanomedicine design.
Questions still open
- Can this platform be adapted for other chemotherapy drugs beyond methotrexate?
- How does the pharmacokinetic profile compare to standard methotrexate formulations?
- What is the long-term safety profile of B-mR9 degradation products?
Common questions
What makes these nanoparticles 'smart'?
Why use cell-penetrating peptides in nanoparticles?
Read the original research
CD44-Mediated Methotrexate Delivery by Hyaluronan-Coated Nanoparticles Composed of a Branched Cell-Penetrating Peptide.
ACS biomaterials science & engineering, 6(1), 494-504
Citation
Yoo, Jisang; Rejinold, N Sanoj; Lee, DaeYong; Noh, Ilkoo; Koh, Won-Gun; Jon, Sangyong; Kim, Yeu-Chun. (2020). CD44-Mediated Methotrexate Delivery by Hyaluronan-Coated Nanoparticles Composed of a Branched Cell-Penetrating Peptide.. ACS biomaterials science & engineering, 6(1), 494-504. https://doi.org/10.1021/acsbiomaterials.9b01724